Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Vose

Showing results (131-140 of 299) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planningApar Kishor Ganti, Stephanie J Lee, Julie M Vose, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2017
Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based TherapyJi Yuan, Timothy C Greiner, Kai Fu, et al.
Cancer Genetics and Cytogenetics|January 11, 2007
Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletionAvadhut D Joshi, John D Dickinson, Ganapati V Hegde, et al.
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|February 9, 2002
Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practiceSamuel C Augustine, Jeffrey P Norenberg, David M Colcher, et al.
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual diseaseJulie M Vose, Graham Sharp, Wing C Chan, et al.
EJNMMI Research|January 9, 2014
18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repairMarielle J Wondergem, Ken Herrmann, Sergei Syrbu, et al.
Biorxiv : the Preprint Server for Biology|March 23, 2026
Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signatureSamantha A Swenson, C Bea Winship, Kasidy K Dobish, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's LymphomaThomas E Witzig, Peter H Wiernik, Timothy Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trialJulie M Vose, Shelly Carter, Linda J Burns, et al.
Pageof 30

Showing results (131-140 of 299) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planningApar Kishor Ganti, Stephanie J Lee, Julie M Vose, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2017
Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based TherapyJi Yuan, Timothy C Greiner, Kai Fu, et al.
Cancer Genetics and Cytogenetics|January 11, 2007
Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletionAvadhut D Joshi, John D Dickinson, Ganapati V Hegde, et al.
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|February 9, 2002
Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practiceSamuel C Augustine, Jeffrey P Norenberg, David M Colcher, et al.
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual diseaseJulie M Vose, Graham Sharp, Wing C Chan, et al.
EJNMMI Research|January 9, 2014
18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repairMarielle J Wondergem, Ken Herrmann, Sergei Syrbu, et al.
Biorxiv : the Preprint Server for Biology|March 23, 2026
Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signatureSamantha A Swenson, C Bea Winship, Kasidy K Dobish, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's LymphomaThomas E Witzig, Peter H Wiernik, Timothy Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trialJulie M Vose, Shelly Carter, Linda J Burns, et al.
Pageof 30